IMNN
$3.13+0.11 (+3.52%)
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II cli...
Recent News
Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ...
Imunon Inc (IMNN) reports significant progress in its pivotal phase 3 trial for ovarian cancer, while navigating financial challenges and market conditions.
Imunon (IMNN) Q3 2025 Earnings Call Transcript
Stacy Lindborg: Thank an you, Peter, and good morning, everyone. Joining me on the call this morning is Dr. Douglas Faller, our Chief Medical Officer, and Ms. Kim Graper, our Interim Chief Financial Officer, who will be reviewing our financial results for the third quarter of 2025. Mr. Michael Tardugno, the Executive Chairman of our board, and Dr. Khursheed Anwer, our Chief Scientific Officer, are also on the line and will be available for Q&A. We continue to make meaningful progress with our proprietary IL-12 immunotherapy, IMNN-001, through the OVATION 3 pivotal phase III trial for newly diagnosed advanced ovarian cancer.
Imunon Inc (IMNN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Imunon Inc (IMNN) reports significant progress in ovarian cancer treatment trials while navigating a tough capital market environment.
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer
The IMNN-001 arm exhibited a median 13-month increase in OS and a median three-month increase in PFS.
Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More
Imunon, Inc. (NASDAQ:IMNN) has completed a private placement, securing $3.25 million in initial funding by selling 7,222,223 shares of common stock or pre-funded warrants at $0.45 each. The deal also grants investors short-term warrants to buy up to 14,444,446 additional shares at the same price. If all warrants are exercised within three years after shareholder […]